{
 "topic": "Gut-restricted therapeutics (biologics and small molecules) across GI and systemic disorders",
 "parts": {
  "P1_design_strategies": {
   "label": "Gut-restriction design & engineering strategies",
   "queries": [
    "gut-restricted small molecule minimal systemic absorption",
    "gut-selective drug design intestinal restriction",
    "non-absorbable oral drug local gastrointestinal action",
    "colon-targeted drug delivery inflammatory bowel disease",
    "gut-restricted JAK inhibitor intestinal",
    "locally acting corticosteroid budesonide MMX ileal release",
    "oral antibody fragment nanobody gastrointestinal delivery",
    "protease-resistant oral biologic gut lumen",
    "pH-triggered colonic release formulation",
    "gut-restricted kinase inhibitor low bioavailability by design",
    "intestinal peptidase-stable oral peptide therapeutic",
    "mucoadhesive epithelium-targeted intestinal drug",
    "minimally absorbed antibiotic gut lumen rifaximin",
    "tissue-restricted immunomodulator gastrointestinal tract"
   ]
  },
  "P2_disease_domains": {
   "label": "Disease domains for gut-restricted therapy",
   "queries": [
    "gut-selective therapy ulcerative colitis",
    "gut-restricted treatment Crohn's disease",
    "locally acting therapy eosinophilic esophagitis",
    "oral non-systemic therapy celiac disease",
    "gut-restricted drug irritable bowel syndrome",
    "non-absorbed therapy Clostridioides difficile infection",
    "gut-restricted agonist type 2 diabetes intestinal",
    "gut-restricted therapy graft-versus-host disease intestinal",
    "locally acting therapy immune checkpoint colitis",
    "intestinal-restricted anti-inflammatory microscopic colitis",
    "gut-restricted therapeutic environmental enteropathy"
   ]
  },
  "P3_mechanism_classes": {
   "label": "Mechanism classes engineered for gut restriction",
   "queries": [
    "gut-selective integrin antagonist alpha4beta7 vedolizumab",
    "sphingosine-1-phosphate receptor modulator ozanimod intestinal",
    "gut-restricted JAK1 inhibitor TD-1473 izencitinib",
    "gut-restricted TYK2 inhibitor intestinal",
    "IL-23 inhibitor gut mucosa inflammatory bowel",
    "bile acid sequestrant gut-restricted",
    "gut-restricted SGLT1 inhibitor glucose intestinal",
    "minimally absorbed TLR agonist intestinal mucosa",
    "gut-restricted anti-TNF oral inflammatory bowel disease",
    "gut-restricted S1P modulator etrasimod colitis",
    "smad7 antisense oral mongersen intestinal",
    "gut-restricted phosphodiesterase inhibitor intestinal"
   ]
  }
 }
}